NID2 and melanoma: Thus far, several studies have highlighted the utility of NID2 as a molecular or serum biomarker for several malignancies including gastric cancer (40), esophageal squamous cell carcinoma (41), ovarian cancer (42), melanoma (43), and breast cancer (44).